This household consumer products name isn’t the flashiest name on Wall Street, but it just pulled off something surprising: a nearly 30% earnings beat, organic growth acceleration, and margin expansion, all while the Street expected a slow bleed. It may not be a high-octane AI play, but it could be one of the stealth trades that keeps working.

While others panic over trade tensions and market swings, a select few companies are quietly thriving.

We’ve identified seven stocks with strong momentum, durable fundamentals, and surprising upside.

This new free report reveals how these names are benefiting from global shifts — not suffering.

The opportunity window could be short.

Get the insights you need before these names get priced in.

[Download your copy now.]

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.

👉 Click here to get our weekly Sunday watchlist sent to your cell for free!

Campbell’s Soup Co

Ticker: CPB | Market Cap: $9.64B | Catalyst: Deep Discount + Supply Chain Efficiency Push

Campbell’s stock has been stuck, down 23% YTD, but the fundamentals are better than the chart suggests. The company is aggressively trimming fat, aiming for $250 million in new savings by 2028, and has already extracted nearly $1 billion over the last few years.

Soup is now less than a quarter of sales, with snacks driving nearly half of the top line. Brands like Pace, Prego, and Goldfish are getting investment behind the scenes, and automation efforts are helping defend margins. With a 4.9% yield and a wide moat rating from Morningstar, CPB may be overlooked by growth investors but is quietly being picked up by income-focused funds.

The stock trades 48% below a fair value estimate of $61. If cost controls hold and volume trends stabilize, CPB could re-rate significantly, especially if the broader market starts rotating into defensives again.

Markets are noisy. We simplify the signal.

Our team just narrowed down 4,400+ stocks into a tight list of 7, all ranked for short-term strength.

No guessing, no Reddit buzz — just stocks that could quietly outperform in the next 30 days.

This system’s past picks have delivered consistently strong returns — and now, it’s your turn.

Get your free copy now before the smart money moves in.

[Grab the 7-Stock Report]

Constellation Brands

Ticker: STZ | Total Assets: $29.3B | Catalyst: Mexican Beer Tariffs + Premium Portfolio Shift

Constellation Brands has taken some hits as well, down 25% YTD, but the business is holding together better than it looks. Beer volume softness and higher tariffs from Mexico have pressured margins, but management is adjusting: more glass bottles, fewer cans, and a premium-only focus in wine and spirits.

STZ still owns Modelo, Corona, and Pacifico, three powerhouse brands, and continues to expand its reach into no-alcohol and seltzer products. Gross margins remain healthy at 51%, and management reaffirmed guidance despite a light Q1. Several major firms, including RBC and Goldman, have reiterated Buy ratings with targets in the $180–$230 range.

With a modest 2.5% yield and a valuation discount versus beverage peers, the setup here is about execution. If beer volumes hold up and margin pressure eases, this could be one of the more tradable mean-reversion setups in the staples category.

Bristol-Myers Squibb

Ticker: BMY | Market Cap: $90.01B | Catalyst: Big Earnings Beat + Market Shrug

Bristol-Myers Squibb blew past expectations in Q2: EPS of $1.46 vs. $1.06 forecast, and revenue of $12.3 billion beat by nearly $1 billion. But the stock barely moved. Investors remain hesitant as the company navigates a post-Revlimid world and transitions into newer therapies.

Still, BMY raised full-year guidance by $700 million and reported 17% year-over-year portfolio growth. Opdivo remains a top player in immuno-oncology, and cardiovascular momentum from Eliquis and newer drugs continues to build. Free cash flow remains strong, and the stock offers a 5.7% dividend yield with low volatility (beta: 0.37).

At under 9x forward earnings, the market seems to be ignoring the beat and baking in all downside. But if the next quarter confirms consistent top-line execution, this valuation gap could start to close quickly, especially for income-seeking investors.

Artificial Intelligence is shaping up to be the most disruptive force since the internet—and a new report shares 5 stocks poised to benefit.

Among them is a little-known "sleeper stock" still flying under Wall Street’s radar.

These picks come from a Zacks senior strategist and target high-growth areas powered by ChatGPT and machine learning.

Early entry could mean massive returns as AI’s $15 trillion boom unfolds.

[Download your free copy of “Zacks Top 5 ChatGPT Stocks” now.]

Clorox Co

Ticker: CLX | Market Cap: $15.2B | Catalyst: EPS Blowout + Organic Sales Rebound

Clorox pulled off a rare beat in a slow-growth environment. Q2 revenue came in 4.5% above last year and beat analyst forecasts, while EPS of $2.87 crushed expectations by nearly 30%. Organic revenue rose 8%, a big jump compared to the same quarter last year.

Operating margins expanded sharply to 20.6% from 13.9%, driven by cost discipline and pricing power. While management offered softer full-year EPS guidance, the market clearly liked what it saw, and the stock responded.

With a nearly 4% dividend yield and a portfolio of trusted consumer brands, Clorox offers stability and upside in a market still uncertain about rate direction and inflation stickiness. If margin strength continues, CLX could see more institutional interest in the second half of the year.

Urban Outfitters

Ticker: URBN | Market Cap: $6.83B | Catalyst: Earnings Beat + Analyst Momentum

Urban Outfitters is riding high after a 34% YTD run, fueled by a monster Q1 earnings report. EPS came in at $1.16, well above estimates, and revenue rose 10.7% year over year. Analysts have responded: JPMorgan just raised its price target to $88, joining a chorus of Buy and Strong Buy ratings.

The retail story is now about more than the core brands. Growth in the company’s Nuuly subscription platform is gaining traction, and margin expansion across banners like Anthropologie and Free People is helping drive EPS upside.

With the stock near 52-week highs, traders may be hesitant to chase, but strong results and multiple price target raises suggest momentum is real. If URBN breaks out above $78 with volume, there’s room to run higher, especially if macro data stays supportive of consumer resilience.

This week’s watchlist is full of surprises, with a sleepy consumer name turning heads, a pharma giant getting no love after a blowout quarter, and a mid-cap retailer grinding to new highs.

Not everything needs to be AI to be actionable. These names show that execution still moves markets, and value still matters.

Stay selective. Stay sharp. Let’s get it.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.